Efficacy

Efficacy of Ilumya (Tildrakizumab) for Psoriasis

Ilumya, with the active ingredient tildrakizumab, is a biologic medication approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Tildrakizumab is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), a cytokine involved in inflammatory processes and linked to psoriasis pathogenesis. Clinical trials have demonstrated that Ilumya is effective in achieving significant skin clearance. In pivotal Phase III trials (reSURFACE 1 and reSURFACE 2), a substantial proportion of patients treated with Ilumya achieved at least a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) score, which is a common measure of psoriasis severity.

Furthermore, many patients treated with Ilumya experienced a PASI 90 response, indicating a 90% reduction in PASI score from baseline, signifying near-complete skin clearance. The long-term efficacy of Ilumya has also been supported, with sustained responses observed in patients over a period of several years. The safety profile of Ilumya was found to be favorable, with low rates of serious adverse events, which is an important consideration for long-term management of psoriasis.

Efficacy of Skyrizi (Risankizumab) for Psoriasis

Skyrizi, containing the active substance risankizumab, is another biologic therapy approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy. Risankizumab is a monoclonal antibody that selectively inhibits IL-23 by binding to its p19 subunit, similar to tildrakizumab. Skyrizi has shown high efficacy in clinical studies, with a significant number of patients achieving clear or almost clear skin. In Phase III trials, such as UltIMMa-1 and UltIMMa-2, Skyrizi demonstrated superior efficacy in achieving PASI 90 and PASI 100 responses compared to placebo and other comparator treatments, including ustekinumab, another IL-12/23 inhibitor.

The efficacy of Skyrizi was not only rapid but also durable, with many patients maintaining skin clearance over time. The UltIMMa trials reported that a majority of patients receiving Skyrizi maintained PASI 90 and PASI 100 responses at one year. The safety profile of Skyrizi was also favorable, with a low incidence of serious adverse events, which is consistent with the safety profiles of other IL-23 inhibitors. The robust efficacy and safety data support the use of Skyrizi as a valuable treatment option for patients with moderate-to-severe plaque psoriasis.